Main description:

This book reviews the recent advances in the development of proteomics-based biomarkers for the non-invasive diagnosis of altitude sickness and explores the potential of antioxidant therapy for this sickness.

The first chapters introduce the associated pathophysiology and provide mechanistic insights into the enhanced generation of reactive oxygen and nitrogen species (RONS), which leads to an increase in oxidative damage to lipids, proteins, and DNA.

The book then highlights the current problems relating to the diagnosis and treatment of altitude sickness and summarizes novel approaches for identifying potential biomarkers and therapeutics. Lastly, it explores the therapeutic efficacy of antioxidant agents.

Contents:

Chapter 1_Hypoxia, Hypoxia accelmatization and Omics tools for assessment. -Chapter 1.1. General Description of various types of hypoxia. -Chapter 1.2.Hypobaric hypoxia in particular and physiological changes. -Chapter 1.3. Hypoxia acclemetization and its molecular framework. -Chapter 1.4. Classical tools of study. -Chapter 1.5.Omics as an emerging tool for revisiting hypoxia. -Chapter 2_High altitude sickness: Introduction.- Chapter 2.1. High altitudes and hypoxia as primary environmental stressor. -Chapter 2.2. Altered physiological response at high altitude. -Chapter 2.3. High allied sickness - milder effects. -Chapter. 2.4. Hypobaric hypoxia and brain, HACE and related cognitive disorders. -Chapter 2.5. Hypobaric hypoxia and Lungs, HAPE and related disorders. -Chapter 2.6. Hypobaric hypoxia and Muscles and related disorders. -Chapter 2.7. Hypobaric hypoxia and Cardiovascular system, Thrombosis, embolism and related disorders. -Chapter 2.8. Integration of various physiological changes and systemic indicators. -Chapter 3_Oxidative stress and proteomic alteration in high altitude. -Chapter 3.1. Mechanism of radical generation in high altitude - effect of oxidative stress. -Chapter 3.2. Oxidative stress during hypoxia. -Chapter 3.3. Mechanism of proteomic alterations in high altitude. -Chapter 3.4. Altered hemostasis in hypoxia.- Chapter 4_Current problems in diagnosis and treatment of high altitude sickness.- Chapter 4.1. Problem of detecting susceptibility. -Chapter 4.2. No available non-invasive technique. -Chapter 4.3. No effective medical intervention except decent. -Chapter 5_Proteomics as potential tool for biomarker discovery. -Chapter 5.1. How proteomics is useful? -Chapter 5.2. Common proteomics tools. -Chapter 5.3. Advanced/emerging proteomics techniques. -Chapter 6_Serum/Plasma proteomics for high altitude related biomarker discovery. -Chapter 6.1.Serum proteomics in animal models of hypoxia. -Chapter 6.2. Serum proteomics in human subjects of hypoxia. -Chapter 6.3. Potential /candidate biomarkers for diagnostic /therapeutic roles. -Chapter 7_Saliva proteomics for non-invasive application. -Chapter 7.1.Importance of saliva as a potential sample. -Chapter 7.2. Less known biomarkers of saliva. -Chapter 7.3. Emerging trends. -Chapter 8_Genomics and Metabolomics insight into hypoxia marker identification. -Chapter 8.1. Genomic fingerprints of high altitude sickness and susceptibility. -Chapter 8.2.Polymorphisms as a potential tool for high altitude adaptation. -Chapter 8.3.Trends in Metabolomics as emerging tool. -Chapter 9_Antioxidant therapies for high altitude sickness. -Chapter 9.1. Conventional phytoextracts. -Chapter 9.2. Novel nanomedicine. -Chapter 9.3. Other antioxidants and metabolic regulators.